The pharmaceutical company Novavax Inc. based in Maryland, USA, announced today that data from the clinical trial of its final stage of the vaccine show that it is over 90% effective against COVID-19 for various variant strains of the virus. The vaccine, which is called NVX-CoV2373, differs as much from mRNA vaccines as those from Pfizer-BioNTech and her Modern, as well as adenovirus-based vaccines, such as those of AstraZeneca - Oxford and Johnson & Johnson. It is based on recombinant nanoparticle technology and the Novavax adjuvant called Matrix-Mon, in order to lead to an immune response.
The research, in which they took part approximately 30.000 volunteers in the US and Mexico, emphasizes that the company is close to applying for emergency approval of its vaccine in the US and other countries, in the third quarter of 2021.
The vaccine developed by Novavax based on proteins was over 93% effective against the dominant variant strains of COVID-19, which are characterized as variants of concern to both scientists and public health officials, according to the company in a statement.
The company also noted that, during the test, the variant strain B.1.1.7, first identified in Britain, became the most commonly observed variant of the virus in the United States.
In addition, o Gregory Glenn, head of research and development at Novavax, told Reuters that the company identified variant strains of COVID-19 that were first identified in Brazil, South Africa and India among the test participants.
This vaccine was 91% effective among volunteers at high risk of serious illness and 100% effective in preventing moderate to severe COVID-19. It was also nearly 70% effective against virus strains that Novavax was unable to recognize, Glenn added. Glenn also noted that it is very important that the vaccine can protect against a virus that mutates rapidly.
Novavax said the vaccine was generally well tolerated among participants.
Concerning side effects of, they were included headache, fatigue and myalgias and these were generally mild. However, a small number of participants had side effects described as serious.
As it turns out, Novavax is near production of 100 million doses per month by the end of the third quarter of 2021, and 150 million installments per month in the fourth quarter of 2021, according to her.
Novavax has repeatedly postponed production forecasts and struggled to access the basic materials and equipment needed to make its vaccine. However, in an invitation to investors, the General Manager, Stanley Erck, stated that major manufacturing barriers have been removed and that all Novavax facilities can now produce the COVID-19 vaccine on a commercial scale. Erck also noted that Novavax has started the process of submitting a request to the regulatory authorities in India in cooperation with the Serum Institute of India (SII), which has been assigned to prepare doses of its vaccine. He also said that what he understands is that SII no longer faces limitations due to shortages of basic materials.
The SII had announced him March that restrictions on US exports of supplies used for vaccines limited its ability to increase production.
This vaccine can be stored in normal refrigerators, thus making it easy to distribute.
Novavax announced the results of the research with press release and now intends to publish them in medical journal, where they will be evaluated by independent experts.